期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

线粒体功能障碍与肾小球足细胞损伤的研究进展 被引量：1

下载PDF
导出
摘要 随着2型糖尿病在全球的蔓延，糖尿病的防治工作已成为世界公共卫生的巨大挑战。据国际糖尿病联盟预测，2030年全世界的糖尿病患病人数将达到5．52亿。随着糖尿病群体的迅猛扩增，糖尿病肾病（diabeticnephropathy，DN）的发生率也逐年增加，业已成为导致终末期肾病最常见的原因。
作者 邢燕 叶山东
机构地区 安徽省立医院内分泌科
出处 《中国实验诊断学》 2014年第10期1726-1728,共3页 Chinese Journal of Laboratory Diagnosis
关键词 肾小球足细胞损伤 线粒体功能障碍 2型糖尿病 国际糖尿病联盟 糖尿病肾病 终末期肾病 公共卫生 患病人数
分类号 R587.2 [医药卫生—内分泌] R692 [医药卫生—泌尿科学]
  • 相关文献

参考文献30

  • 1Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030[J]. Diabetes Res Clin Pract,2011,94(3) :311.
  • 2Pyram R, Kansara A, Banerji MA, et al. Chronic kidney disease and diabetes[M]. Maturitas, 2012,71 (2) : 94.
  • 3Sayed AA. Ferulsinaic acid attenuation of diabetic nephropathy [J]. Eur J Clin Invest,2013,43(1) :56.
  • 4Gunst J,Derese I, Aertgeerts A, et al. Insufficient autophagy contributes to mitochondrial dysfunction, organ failure, and adverse outcome in an animal model of critical illness[J]. Crit Care Med, 2013,41(1) :177.
  • 5Davis RE, Williams M. Mitochondrial function and dysfunction : an update[J]. J Pharmacol Exp Ther,2012,342(3) :598.
  • 6邢燕,叶山东,陈玉米,陈燕,范爱红,程涛,方文祥.不同剂量盐酸吡格列酮对糖尿病大鼠尿podocalyxin排泄的影响[J].中国糖尿病杂志,2013,21(2):175-177. 被引量：4
  • 7Xing Y,Ye S,Hu Y,Chen Y. Podocyte as a potential target of in- flammation: role of pioglitazone hydrochloride in patients with type 2 diabetes[J]. Endoer Pratt,201-2,18(4) :493.
  • 8Tsuruoka S, Hiwatashi A, Usui J, et al. The mitoehondrial SIRT1 PGC-la axis in podocyte injury[-J]. Kidney Int, 2012,82 (7) :735.
  • 9Yuan Y, H uang S, Wang W, et al. Activation of peroxisome prolif- erator-activated receptor-7 coactivator is ameliorates mitochon- drial dysfunction and protects podocytes from aldosterone-indueed injury[J]. Kidney Int,2012,82(7) :771.
  • 10Mancuso M,Orsucci D,Filosto M,et al. Drugs and mitoehondrial diseases:40 queries and answers[J]. Expert Opin Pharmacother, 2012,13(4) : 527.

二级参考文献9

  • 1Hara M, Yanagihara T, Kihara I,et al Apical cell membranes areshed into urine from iiqured podocytes: a novel phenomenon ofpodocyte injtuty. J Am Soc N^)hrol,2005 * 16 ? 408-416.
  • 2Kanno K, Kawachi H,Uchida Y, et al Urinary sedimentpcxlocalyxin in children with glomerular diseases. Nephron ClinPract,2003,95: c9l-c99.
  • 3Nielsen JS, McNagny KM. The role of podocalyxin in healthand disease. J Am Soc Nephrol f 2009,20 : 1669-1676.
  • 4Economou CG, Kitsiou PV, Tania AK,et al Enhancedpodocalyxin expression alters the structure of podocyte basalsurface. J Cell Sri,2004,117:3281-3294.
  • 5Koop K, Eikmans M,Baelde HJ. et al Expression of podo-cyte-assodated molecules in acquired human kidney diseases. JAm Soc Nephrol,2003,14: 2063-2071.
  • 6Kanjanabuch T, Ma LJ, Chen J, et al PPAR-gamm^ agonistprotects podocytes from injury. Kidney Int, 2007, 71:1232-1239.
  • 7Mglio G, Rosa AC,Rattazzi L, et al The subtypeS of peroxi-some proliferator-activated receptors expressed by human podo-cytes and their role in decreasing podocyte injury. Br J Pharma-col,2011,162:111-125.
  • 8Okada T, Wada J, Hida K, et al Thiazolidinediories amelio-rate diabetic nephropathy via cell cycle-dependent mechanisms.Diabetes, 2006,55 : 1666-1677.
  • 9杨俏玲,何兰杰,刘萍,李红兵,秦璟.罗格列酮干预对糖尿病大鼠肾病的影响[J].中国糖尿病杂志,2008,16(5):313-316. 被引量：3

共引文献3

同被引文献15

引证文献1

二级引证文献3

中国实验诊断学
2014年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部